Although infrastructures that collect, process, store, and distribute human biospecimens are working to improve access, no single accepted business model exists that enables long-term operation of biobanks. To address this sustainability problem, an international expert group (table S1) developed a transparent tool that sets actual costrelated prices for access to specimens and data. Here we describe this process and apply the tool to set access prices for a variety of biomedical translation partnerships.
BIOBANK BOTTLENECK
As repositories of biological materials (tissues, cells, and microorganisms) and databases that contain molecular, physiological, and structural information relevant to these collections, biobanks are part of the essential infrastructure for life science research. Indeed, the goal of hospital-based biobanks is to make high-quality biological resources available to academic and industrial (1) research settings in accord with international standards that comply with societal values and ethical and regulatory policies. However, academic biomedical research and biotechnology and pharmaceutical research and development all suf er from blocks in access to human biospecimens and their associated data.
National and international initiatives have laid the groundwork for facilitating access to large-scale collections of biological resources. Scientif c associations and international organizations have released guidelines for best practices in biobanking and have created bodies to support improved harmonization and to contribute to the building of an international biobank community [see www.oecd.org/health/biotech/ 38777417.pdf and (2)]. Furthermore, the European Union (EU) funded the Biobanking and BioMolecular resources Research Infrastructure (BBMRI) project to acquire the information necessary for the development of a pan-European biobank network (3, 4) . T e BBMRI project engaged with more than 320 biobanks in EU member and associated states to assemble the European Research Infrastructure Consortium (BBMRI-ERIC; http://bbmri.eu), which is now constructing an EU biobank network. Such initiatives contribute to the provision of infrastructure that can serve current and future biobanking needs.
However, biomedical research, innovation, and translation require this infrastructure to be maintained and improved over many decades. For biobanks to achieve longevity, they must be f nancially sustainablea key issue in biomedical translation that has not yet been resolved. It is rare for biobanks to have access to secure long-term funding. Most rely on short-term institutional sources or project-related research income (5) . Strategies are emerging that seek to recover the costs of data and biospecimen processing and retrieval (6) . However, anecdotal evidence suggests that these strategies are dif cult to deploy so as to ensure longterm sustainability. T is situation threatens to waste large public investments in biobank construction and to hinder scientif c advances through loss or fragmentation of the biological resources that they manage. Achieving f nancial sustainability is further complicated by the fact that the operation of a biobank has substantial overhead costs. Moreover, biobanks of en rely on voluntary contributions from medical personnel and health care systems, which makes specif cation of the cost structure of the biobank diff cult. T is unclear funding system is at odds with the clear need-especially for chronic diseases-to annotate biological resources with outcome information over many years.
BY THE NUMBERS
T e selling of human biological specimens for prof t does not comply with EU ethical values and legal requirements (7) . Hence to ensure compliance, it is essential to show that prices for access to resources are transparently related to reasonable costs. Such cost assessment then becomes a tool that provides essential information to donors, patient groups, and the general public about the nonprof t activity of a biobank.
Recognizing that sustained biobanking requires f nancial sustainability, we assembled a group of biobank experts from the EU and the United States to (i) enumerate the dif erent steps and variables that could be included in cost assessment of biospecimens and annotations; (ii) seek a consensus on a minimal variable set that should be included in such an assessment in the future; and (iii) propose a policy to assess the cost of these various steps and variables.
T e expert group identif ed 46 dif erent biobanking activity tasks and then assigned to each task an indicator of the expertise required (A: high; B: medium; C: low) and an indicator of the duration or complexity of the task (1: <1 hour/low complexity; 2: 1 to 2 hours/medium complexity; 3: >2 hours/ high complexity) (cost-estimate pricing tool is described in supplementary methods). Related tasks were grouped together to form f ve blocks (prebanking data; collection of biological specimens; collection of data related to biological specimens; expertise; and administration and management) ( A calculation grid developed by an international expert group was tested across biobanks in six countries to evaluate costs for collections of various types of biospecimens. The assessment yielded a tool for setting specimen-access prices that were transparently related to biobank costs, and the tool was applied across three models of collaborative partnership.
FOCUS logical resources (tumor tissue, blood, other biological f uids, DNA, fungi, and bacteria).
Analysis of the questionnaires permitted estimates of costs based on expertise, labor time and rates, and biospecimen type (table S3; cost-estimate pricing tool is described in supplementary methods). As expected, cost dif erences were related to the type of biospecimens collections (for example, tumor blocks, 1500 €, versus DNA from blood, 460 €, in France), the labor cost (for example, blood DNA samples in United Kingdom, 490 €, versus Poland, 239 €), and the complexity of the task (cryopreserved tissue sample, 1639 €, versus formalin-f xed paraf nembedded tissue sample, 628 €, in Austria). One remarkable f nding of this assessment was that the highest fraction of the cost (from 60 to 80%) was attributed to the management and biobanking expertise required to ensure compliance with quality standards, ethical standards, and legal requirements, regardless of the nature of the biological resource. T e most important dif erences arose as a result of the varying range of activities of biobanks; depending on the bank, functions ranged from those that required minimal handling and expertise (for example, storage and distribution) to those that required an extensive set of skilled activities (such as data management, biostatistical analysis, and transformation of derivative products). It is noteworthy that publicly available prices for access to biospecimens in many biobanks are usually calculated based on a partial assessment of the cost to acquire and maintain that resource. However, this pricing approach o% en omits the most expensive steps of the process: preanalytical biospecimen processing, annotation of biological samples with detailed medical information, biobank management, and skilled expertise.
Our data suggest that biobank f nancial sustainability is unlikely to be achieved with the use of a cost-recovery policy based on setting prices for users that ref ect biobanking costs in full. Biomedical research funders would f nd the prices unpalatable. Institutions would be under pressure to disclose their detailed f nancial arrangements so as to justify their prices. Moreover, biobanks would need to raise prices still further to fully include transaction costs (accountancy, debt-chasing, regular analysis of the changing costs of processes) and the costs of ensuring contract compliance. In addition, from our experience, biobank maintenance via cost recovery is hampered by the reality that maintenance costs are continuous, 
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while income is irregular and unpredictable. Although biobanking is fragmented, this problem can only be addressed by raising prices still further.
However, even if full cost recovery is impractical, the pricing tool we describe here may, for now, be useful for evaluating biobank policies aimed at some recovery of costs and in structuring public-public and public-private collaborative partnerships that share project costs (8, 9) . T e extension and deepening of such partnerships is widely recognized for its importance in improving human health and is one way of strengthening the f nancial position of biobanks. T ese partnerships may adopt one of three general cost models [ Table 2 ; described elsewhere in greater detail (9) ]-full cost (model 1), partial cost plus fee (model 2), and marginal cost (model 3). T e models dif er in the degree of collaboration between the partners, and this is ref ected in dif ering prices; the table shows the prices we calculated based on our analysis of responses to our calculation grid. T us, the participation of the biobank must be discussed before contracts between parties are written. T is approach may benef t from template licensing agreements in order to avoid any delay in collaborative projects.
Further work is required to def ne a full solution for the problem of long-term f nancial sustainability of biobanking. T is work should entail investigations into attempted solutions for the problem of long-term f nancial sustainability of research infrastructure in other areas of the natural sciences. Also needed are studies of the role of biobanking simultaneously for research and for health service delivery in an era of personalized (or stratif ed) medicine.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/ 6/261/261fs45/DC1 Supplementary Methods Table S1 . Expert group. Restricted to specifi c project MTA is part of a collaboration agreement
Intellectual property
Not claimed User has right of fi rst refusal to IP IP shared as per collaboration agreement
Publications
Biobank acknowledged Biobank acknowledged and described in Materials and Methods
Co-authorship + biobank acknowledged and described in Materials and Methods
Costs
Full cost of each sample Percent of full cost plus a contribution to the biobank
Consumables and handling costs
Example of prices / sample 1000 to 2000 € 200 to 500 € 10 to 100 €
